Home Medizin IPIAD erweitert die Standardtherapie für das duktale Adenokarzinom des Pankreas

IPIAD erweitert die Standardtherapie für das duktale Adenokarzinom des Pankreas

von NFI Redaktion


A new research perspective has been published in Oncoscience (Volume 11) on February 7th, 2024, titled „IPIAD – an augmentation regimen added to the standard treatment of ductal adenocarcinoma of the pancreas using already marketed, reused drugs Irbesartan, Pyrimethamine, Itraconazole, Azithromycin, and Dapsone.“

In this new article, researcher Richard E. Kast from the IIAIGC Study Center presents the data and reasons for adding five generic non-oncology drugs from general medicine to gemcitabine and nab-paclitaxel, a current standard cytotoxic chemotherapy for ductal adenocarcinoma of the pancreas. The regime, known as IPIAD, uses the angiotensin receptor blocker (ARB) Irbesartan for hypertension, the old antimicrobial drug Pyrimethamine for toxoplasmosis or malaria, the old antifungal Itraconazole, the old broad-spectrum antibiotic Azithromycin, and the old antibiotic Dapsone.

„By reviewing selected growth-driving systems that are active in ductal adenocarcinoma of the pancreas and then comparing these with detailed data on the additional properties of the IPIAD drugs, one can predict the clinical benefits and the slowing of the growth of ductal adenocarcinoma of the pancreas through this augmentation regimen.“

Source:

Journal Reference:

Kast, RE (2024). IPIAD – an augmentation regimen added to the standard treatment of ductal adenocarcinoma of the pancreas using already marketed, reused drugs Irbesartan, Pyrimethamine, Itraconazole, Azithromycin, and Dapsone. Oncoscience. doi.org/10.18632/oncoscience.594.

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.